Importantly, elevated ITGB4 levels were associated with a worse prognosis of R0-resected patients with serous ovarian cancer, supporting a recent study identifying ITGB4 as an independent predictor of adverse progression-free survival in ovarian cancer [46]. Here, ITGB4 is linked to ovarian cancer.